JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on SGMT stock, giving a Buy rating on November 25.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Debanjana Chatterjee has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Sagimet Biosciences’ pipeline. The company’s lead program, Denifanstat, is progressing with a Phase 1 study for a combination treatment for F4 MASH, with data expected in the first half of 2026. If the results are favorable, a Phase 2 trial could commence, potentially providing early insights based on non-invasive tests.
Additionally, Sagimet’s second candidate, TVB-3567, is undergoing a Phase 1 trial for acne treatment, with results anticipated by mid-2026. The company also plans to initiate a Phase 2 trial for moderate-to-severe acne, focusing on lesion reduction and treatment success. Furthermore, Sagimet’s financial position is strong, with $125 million in cash expected to support operations until the third quarter of 2027, providing a solid runway for continued development.
In another report released on November 25, Canaccord Genuity also maintained a Buy rating on the stock with a $28.00 price target.